- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2018
- Public Summary Document (PSD) March 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2018 PBAC Meeting - Word
Eculizumab – March 2018
Eculizumab: Solution concentrate for I.V. infusion 300 mg in 30 mL; Soliris®
Last updated
29 June 2018